clinical trial · NCT07301658
Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis.
i+Med S.Coop.·N/A·completed·n = 42
Atopic Dermatitis (AD)Novel dermocosmetic product containing cannabidiol (CBD) and Annona cherimola fruit extract.
brief summary
A 56-day clinical study evaluated Revodiol Calming Cream on pediatric and adult participants with mild to moderate atopic-prone skin under dermatological supervision. The product was applied twice daily, and efficacy was assessed through dermatological scoring, instrumental measurements, and subjective questionnaires. Results aimed to show improvements in barrier function, hydration, skin texture, and reduction of erythema, dryness, and pruritus, with feedback on comfort and quality of life.
started
Feb 27, 2023
primary completion
Jun 6, 2023
completion
Aug 7, 2024
last updated
Dec 24, 2025
official title
Evaluation of the Effectiveness and Safety of Revodiol Calming Cream® in the Management of Atopic Dermatitis Under Dermatological Control.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol